A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TITAN-RCC
- 13 Jul 2018 Planned End Date changed from 1 Jan 2021 to 1 Jul 2021.
- 13 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated